Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary RESTORE technology platform, is a muco-adhesive CHITOSAN based biopolymer matrix, which in the case of Ortho-R, is mixed with patient conditioned plasma of a concentrate of proteins/growth factors (Platelet-Rich Plasma or “PRP”) to deliver biologics to increase the healing rates of occupational and sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer-biologics hybrid combination can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bioactivity and residency of our proprietary biopolymer, Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com. Also follow us on LinkedIn and Twitter.
Ortho Regenerative Technologies Inc. (ORTH)
le 5 octobre/October 2017
The common shares of Ortho Regenerative Technologies Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com.